DOI QR코드

DOI QR Code

Serum CEA Level Change and Its Significance Before and after Gefitinib Therapy on Patients with Advanced Non-small Cell Lung Cancer

  • Qin, Hai-Feng (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) ;
  • Qu, Li-Li (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) ;
  • Liu, Hui (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) ;
  • Wang, Sha-Sha (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science) ;
  • Gao, Hong-Jun (Department of Pulmonary Neoplasms Internal Medicine, The Affiliated Hospital of Academy of Military Medical Science)
  • Published : 2013.07.30

Abstract

Objective: The aim of this study was to explore change and significance of serum carcino-embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty patients with advanced NSCLCs in III~IV stages were selected as study objects given gefitinib therapy combined with routine local radiotherapy until tumor progression or intolerable toxicity. After treatment, all patients were divided into control and non-control groups according to the results of evaluation based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors in 2009). Peripheral fasting blood from all patients was collected in the early morning and serum CEA was assessed by electro-chemiluminescence immunoassay (ECLIA) before and after treatment. Before treatment, patients were divided into high CEA group (CEA level > 50 ng/mL) and low CEA group (CEA level ${\leq}$ 50 ng/mL). Adverse reactions were noted and progression-free survival (PFS) in both groups was recorded after long-term follow-up that ended in December, 2012. Results: There was no difference between control and non-control groups in CEA level before treatment (P>0.05), whereas serum CEA decreased more markedly lower in the control group after treatment (P<0.01). All patients were divided into high CEA group (26) and low CEA group (14) according to serum CEA level. There was no statistically significant difference between two groups in adverse reactions (P>0.05) but the rate in former group was lower. Additionally, survival rates at 9 and 12 months in high CEA group were clearly higher than in the low CEA group (P<0.01). Conclusions: Serum CEA level can serve as a biochemical index to evaluate the prognosis with gefitinib treatment for NSCLC.

Keywords

Non-small-cell lung cancer;advanced;gefitinib;carcino-embryonic antigen

References

  1. Sakai A, Kasahara K, Sone T (2013). Detection of EGFR T790M mutation in pericardial effusion from a non-small cell lung cancer patient with erlotinib therapy. Case Rep Oncol, 6, 15-20. https://doi.org/10.1159/000345947
  2. Sechler M, Cizmic AD, Avasarala S, et al (2013). Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategies. Pharmgenomics Pers Med, 6, 25-36.
  3. Shrestha S, Joshi P (2012). Gefitinib monotherapy in advanced non-small-cell lung cancer: a retrospective analysis. J Nepal Med Assoc, 52, 66-71.
  4. Sudo M, Chin TM, Mori S, et al (2013). Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer. Cancer Chemother Pharmacol, 71, 1325-34. https://doi.org/10.1007/s00280-013-2132-y
  5. Tanaka K, Hata A, Kaji R, et al (2013). Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation. J Thorac Oncol, 8, 892-8. https://doi.org/10.1097/JTO.0b013e31828c3929
  6. Tomonaga N, Nakamura Y, Yamaguchi H, et al (2013). Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma. Clin Lung Cancer.
  7. Wheler J, Falchook G, Tsimberidou AM, et al (2013). Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD anderson cancer center phase I population. Oncotarget, 4, 772-84.
  8. Morabito A, Costanzo R, Rachiglio AM, et al (2013). Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations. J Thorac Oncol, 8, e59-60. https://doi.org/10.1097/JTO.0b013e318286cc26
  9. Wu C, Li F, Jiao SC (2012). Prognostic factors for survival of patients with extensive stage small cell lung cancer--a retrospective single institution analysis. Asian Pac J Cancer Prev, 13, 4959-62. https://doi.org/10.7314/APJCP.2012.13.10.4959
  10. Acunzo M, Romano G, Palmieri D, et al (2013). Cross-talk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci U S A, 110, 8573-8. https://doi.org/10.1073/pnas.1302107110
  11. Al Dayel F (2012). EGFR mutation testing in non-small cell lung cancer (NSCLC). J Infect Public Health, 5, S31-4. https://doi.org/10.1016/j.jiph.2012.09.008
  12. Al Zobair AA, Al Obeidy BF, Yang L, et al (2013). Concomitant overexpression of EGFR and CXCR4 is associated with worse prognosis in a new molecular subtype of non-small cell lung cancer. Oncol Rep, 29, 1524-32.
  13. Araki T, Yashima H, Shimizu K, et al (2012). Review of the treatment of non-small cell lung cancer with gefitinib. Clin Med Insights Oncol, 6, 407-21.
  14. Aydiner A, Yildiz I, Seyidova A (2013). Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status. Asian Pac J Cancer Prev, 14, 3255-61. https://doi.org/10.7314/APJCP.2013.14.5.3255
  15. Chen G, Kronenberger P, Teugels E, et al (2013). Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents. Biochem Biophys Res Commun, 431, 623-9. https://doi.org/10.1016/j.bbrc.2012.12.070
  16. Han Y, Wang XB, Xiao N, et al (2013). mRNA Expression and Clinical Significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in Postoperative Patients with Non-Small Cell Lung Cancer. Asian Pac J Cancer Prev, 14, 987-90. https://doi.org/10.7314/APJCP.2013.14.5.2987
  17. Jeon WI, Ryu PD, Lee SY (2012). Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells. Anticancer Res, 32, 5279-84.
  18. Karachaliou N, Costa C, Gimenez-Capitan A, et al (2013). BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations. J Thorac Oncol, 8, 295-300. https://doi.org/10.1097/JTO.0b013e31827db621
  19. Lee E, Keam B, Kim DW, et al (2013). Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol, 8, 1069-74. https://doi.org/10.1097/JTO.0b013e318294c8e8
  20. Lee KH, Lee KY, Jeon YJ, et al (2012). Gefitinib in Selected Patients with Pre-Treated Non-Small-Cell Lung Cancer: Results from a Phase IV, Multicenter, Non-Randomized Study (SELINE). Tuberc Respir Dis (Seoul), 73, 303-11. https://doi.org/10.4046/trd.2012.73.6.303
  21. Liang J, Qian Y, Xu D, et al (2013). Serum Tumor Markers, Hypoxia-Inducible factor-$1{\alpha}$ HIF-$1{\alpha}$ and Vascular Endothelial Growth Factor, in Patients with Non- small Cell Lung Cancer Before and after Intervention. Asian Pac J Cancer Prev, 14, 3851-4. https://doi.org/10.7314/APJCP.2013.14.6.3851
  22. Liu YC, Zhou SB, Gao F, et al (2013). Chemotherapy and late course three dimensional conformal radiotherapy for treatment of patients with stage III non- small cell lung cancer. Asian Pac J Cancer Prev, 14, 2663-5. https://doi.org/10.7314/APJCP.2013.14.4.2663
  23. Lopez-Rios F, Angulo B, Gomez B, Mair D, et al (2013). Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol, 66, 381-5. https://doi.org/10.1136/jclinpath-2012-201240
  24. Louis RA, Rajendranath R, Ganesan P, et al (2012). First report of upfront treatment with Gefitinib in comparison with chemotherapy in advanced non-small cell lung cancer patients from south India: Analysis of 120 patients. Indian J Med Paediatr Oncol, 33, 146-54. https://doi.org/10.4103/0971-5851.103141
  25. Lu YY, Huang XE, Xu L, et al (2013). Potential predictors of sensitivity to pemetrexed as first-line chemotherapy for patients with advanced non-squamous NSCLCs. Asian Pac J Cancer Prev, 14, 2005-8. https://doi.org/10.7314/APJCP.2013.14.3.2005
  26. Maftouh M, Avan A, Galvani E, et al (2013). Molecular mechanisms underlying the role of microRNAs in resistance to epidermal growth factor receptor-targeted agents and novel therapeutic strategies for treatment of non-small-cell lung cancer. Crit Rev Oncog, 18, 317-26. https://doi.org/10.1615/CritRevOncog.2013007191

Cited by

  1. Clinical Study on Mannan Peptide Combined with TP Regimen in Treating Patients with Non-small Cell Lung Cancer vol.14, pp.8, 2013, https://doi.org/10.7314/APJCP.2013.14.8.4801
  2. Preliminary Evaluation of Clinical Utility of CYFRA 21-1, CA 72-4, NSE, CA19-9 and CEA in Stomach Cancer vol.15, pp.12, 2014, https://doi.org/10.7314/APJCP.2014.15.12.4933
  3. Serum Carcinoembryonic Antigen Levels before Initial Treatment are Associated with EGFR Mutations and EML4-ALK Fusion Gene in Lung Adenocarcinoma Patients vol.15, pp.9, 2014, https://doi.org/10.7314/APJCP.2014.15.9.3927
  4. Correlation between Serum Carcinoembryonic Antigen Level and Histologic Subtype in Resected Lung Adenocarcinoma vol.16, pp.9, 2015, https://doi.org/10.7314/APJCP.2015.16.9.3857
  5. Label-free Electrochemical Aptasensor for Carcino-embryonic Antigen Based on Ternary Nanocomposite of Gold Nanoparticles, Hemin and Graphene vol.28, pp.5, 2015, https://doi.org/10.1002/elan.201500593